Biomarkers for evaluating the clinical response to immune checkpoint inhibitors in renal cell carcinoma (Review)

被引：1

作者：

Gonzalez-Garza, Raquel ^{[1
]}

Gutierrez-Gonzalez, Adrian ^{[2
]}

Salinas-Carmona, Mario Cesar ^{[1
]}

Mejia-Torres, Manuel ^{[1
]}

机构：

[1] Autonomous Univ Nuevo Leon, Univ Hosp Jose Eleuterio Gonzalez, Immunol Serv, Monterrey 64460, Nuevo Leon, Mexico

[2] Autonomous Univ Nuevo Leon, Univ Hosp Jose Eleuterio Gonzalez, Urol Serv, Monterrey 64460, Nuevo Leon, Mexico

来源：

ONCOLOGY REPORTS | 2024年 / 52卷 / 06期

关键词：

renal cell carcinoma; immunotherapy; predictive biomarkers; tumor-immune microenvironment; immune checkpoint blockade; NIVOLUMAB; EXPRESSION; THERAPY;

D O I：

10.3892/or.2024.8823

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal cell carcinoma (RCC) is a highly aggressive neoplastic disease of the renal parenchyma that is characterized by an intrinsic resistance to cytotoxic chemotherapy; for this reason, curative treatment is only achieved through surgical intervention in its early stages. The successful treatment of advanced or metastatic RCC will require the combined use of novel targeted therapies such as tyrosine kinase inhibitors, vascular endothelial growth factor blockers and immune checkpoint blockade therapies. Unfortunately, not all patients are candidates for such treatments, and at present, it is not possible to predict a patient's therapeutic response or likelihood to develop treatment-associated complications. The present review described the literature focusing on the use of biomarkers for predicting patients' responses to therapies that induce immune checkpoint blockade in RCC.

引用

页数：10

共 80 条

[1] The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma [J].

Ascierto, Maria Libera ;

McMiller, Tracee L. ;

Berger, Alan E. ;

Danilova, Ludmila ;

Anders, Robert A. ;

Netto, George J. ;

Xu, Haiying ;

Pritchard, Theresa S. ;

Fan, Jinshui ;

Cheadle, Chris ;

Cope, Leslie ;

Drake, Charles G. ;

Pardoll, Drew M. ;

Taube, Janis M. ;

Topalian, Suzanne L. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (09) :726-733

[2] Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) [J].

Atkins, Michael B. ;

Jegede, Opeyemi A. ;

Haas, Naomi B. ;

McDermott, David F. ;

Bilen, Mehmet A. ;

Stein, Mark ;

Sosman, Jeffrey A. ;

Alter, Robert ;

Plimack, Elizabeth R. ;

Ornstein, Moshe ;

Hurwitz, Michael ;

Peace, David J. ;

Signoretti, Sabina ;

Denize, Thomas ;

Cimadamore, Alessia ;

Wu, Catherine J. ;

Braun, David ;

Einstein, David ;

Catalano, Paul J. ;

Hammers, Hans .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) :2913-+

[3]

Bahadoram S., 2022, G Ital Nefrol, V39, P2022, DOI DOI 10.1007/S11912-023-01437-X

[4] Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma [J].

Ballesteros, Pablo Alvarez ;

Chamorro, Jesus ;

Roman-Gil, Maria San ;

Pozas, Javier ;

Dos Santos, Victoria Gomez ;

Granados, Alvaro Ruiz ;

Grande, Enrique ;

Alonso-Gordoa, Teresa ;

Molina-Cerrillo, Javier .

CANCERS, 2021, 13 (23)

[5] Progressive immune dysfunction with advancing disease stage in renal cell carcinoma [J].

Braun, David A. ;

Street, Kelly ;

Burke, Kelly P. ;

Cookmeyer, David L. ;

Denize, Thomas ;

Pedersen, Christina B. ;

Gohil, Satyen H. ;

Schindler, Nicholas ;

Pomerance, Lucas ;

Hirsch, Laure ;

Bakouny, Ziad ;

Hou, Yue ;

Forman, Juliet ;

Huang, Teddy ;

Li, Shuqiang ;

Cui, Ang ;

Keskin, Derin B. ;

Steinharter, John ;

Bouchard, Gabrielle ;

Sun, Maxine ;

Pimenta, Erica M. ;

Xu, Wenxin ;

Mahoney, Kathleen M. ;

McGregor, Bradley A. ;

Hirsch, Michelle S. ;

Chang, Steven L. ;

Livak, Kenneth J. ;

McDermott, David F. ;

Shukla, Sachet A. ;

Olsen, Lars R. ;

Signoretti, Sabina ;

Sharpe, Arlene H. ;

Irizarry, Rafael A. ;

Choueiri, Toni K. ;

Wu, Catherine J. .

CANCER CELL, 2021, 39 (05) :632-+

[6] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].

Bray, Freddie ;

Laversanne, Mathieu ;

Sung, Hyuna ;

Ferlay, Jacques ;

Siegel, Rebecca L. ;

Soerjomataram, Isabelle ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) :229-263

[7] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma [J].

Brown, Landon C. ;

Zhu, Jason ;

Desai, Kunal ;

Kinsey, Emily ;

Kao, Chester ;

Lee, Yong Hee ;

Pabla, Sarabjot ;

Labriola, Matthew K. ;

Tran, Jennifer ;

Dragnev, Konstantin H. ;

Tafe, Laura J. ;

Dayyani, Farshid ;

Gupta, Rajan T. ;

McCall, Shannon ;

George, Daniel J. ;

Glenn, Sean T. ;

Nesline, Mary K. ;

George, Saby ;

Zibelman, Matthew ;

Morrison, Carl ;

Ornstein, Moshe C. ;

Zhang, Tian .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)

[8] Inborn errors of immunity: A field without frontiers [J].

Bucciol, Giorgia ;

Delafontaine, Selket ;

Meyts, Isabelle ;

Poli, Cecilia .

IMMUNOLOGICAL REVIEWS, 2024, 322 (01) :15-27

[9] Epidemiology of Renal Cell Carcinoma: 2022 Update [J].

Bukavina, Laura ;

Bensalah, Karim ;

Bray, Freddie ;

Carlo, Maria ;

Challacombe, Ben ;

Karam, Jose A. ;

Kassouf, Wassim ;

Mitchell, Thomas ;

Montironi, Rodolfo ;

O'Brien, Tim ;

Panebianco, Valeria ;

Scelo, Ghislaine ;

Shuch, Brian ;

van Poppel, Hein ;

Blosser, Christopher D. ;

Psutka, Sarah P. .

EUROPEAN UROLOGY, 2022, 82 (05) :529-542

[10]

Buscheck Franziska, 2020, Oncotarget, V11, P237, DOI 10.18632/oncotarget.27428

← 1 2 3 4 5 6 7 8 →